Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial

A total of 97% of subjects underwent successful study product injections; all allo-mesenchymal stromal cells–assigned subjects received the target dose of cells.